New Market Study Published: Pharmaceutical Companies Performance Tables 2010

Feb. 13, 2011 - PRLog -- In today's challenging market, business planners and commercial management must ask themselves some key questions, such as...

Who are the winners and losers in terms of revenue growth?
Which companies have succeeded in maintaining or growing profits?
Overall R&D investment from the top 10 companies fell between 2008 and 2009 by US$421 million from US$57.54 billion to US$57.12 billion - yet some companies maintained or expanded R&D spend. Who were they?
Who are the fastest growers? 10 companies with joint 2005 sales of US$2.55 billion posted sales of $US13.06 billion in 2009. Who were they?
Which companies are cash rich or cash poor?

Pharmaceutical Company Performance Tables
The answers to thousands of key questions are in the new 2010 edition

This essential fully-updated business reference report compares and contrasts the performance and fortunes of leading pharmaceutical companies and places them in easy-to-read tables. Importantly, in addition to rankings, the new edition of the report includes the individual results for 162 companies and up to five years of key data from the balance sheet, income statement and cash flow.

Key Facts & Benefits of this report:

Full 2009 year-end figures
Contains a wide range of detailed performance rankings for more than 160 leading pharmaceutical companies
Includes individual company results
Provides up to five years of trend data
Available in print or pdf with web access included free of charge!

Trends affecting the global industry

The challenging economic environment continues to affect health spending in many countries which has impacted the pharmaceutical industry's commercial performance. Issues which are affecting companies' performance, include...

The number of blockbuster drugs which have lost patent protection, and the number is set to rise over the coming years, have not been replaced by new products offering significant therapeutic advances

Those products which have been launched - increasingly in the biological area - have attracted criticism and objection from health payers due to their high cost

Many companies continue to post rising revenues and increasing profits, although for many it is against a background of cost cutting

Mergers and acquisitions, and especially technology/product acquisition, have taken an increasing role in market entry/expansion plans

Generic competition continues to erode the profits of off-patent products, although spending constraints and rising competition are creating pressure in the generic sector.
Pharmaceutical Companies Performance Tables
A unique opportunity to assess companies' financial and operating performances.

Use it for...

Competitor analysis
Acquisition targeting
Partnering and licensing background
PR and Marketing
Performance benchmarking

Just some of the 162 companies in the 2010 edition... Abbott Laboratories
Abraxis BioScience
Ajinomoto
Alcon Laboratories
Allergan
Amgen
Amylin Pharmaceuticals
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
BTG International
Celgene
Chugai
CSL Limited
Cubist Pharmaceuticals
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dendreon
Dr Reddy's Labs
Egis
Eisai
Elan
Eli Lilly
Endo Pharmaceuticals
Enzon Pharmaceuticals
Eurand
Forest Laboratories
Gedeon Richter
Genzyme
Gilead Sciences
GlaxoSmithKline
Hospira
Human Genome Sciences
ImmunoGen
Incyte
Inspire Pharmaceuticals
Ipsen
Isis Pharmaceuticals
Johnson & Johnson
KRKA
Kyowa Kirin
Lundbeck
Mannkind
Merck & Co
Merck KGaA
Mitsubishi Tanabe Pharma
Mylan Laboratories
Nipro
Novartis
Novo Nordisk
NPS Pharmaceuticals
Nycomed
Ono Pharmaceuticals
Orion
OSI Pharmaceuticals
Otsuka
Pfizer
Procter & Gamble
Ranbaxy
Recordati
Regeneron Pharmaceuticals
Roche
sanofi-aventis
Sawai
Shionogi
Shire Pharmaceuticals
Stada Arzneimittel
Takeda
Teva Pharmaceutical Industries
Theravance
UCB
Vertex Pharmaceuticals
XOMA
ZymoGenetics

Extensive Contents
Key Financial Indicators include:
Pharmaceutical Sales
Total Revenues
Cost of Sales
Operating Income
Net Income
Earnings per Share
R&D Expenditure
Capital Expenditure
Return on Capital Employed
Total Assets
Cash in Hand
Employees
Companies are also ranked by:
Productivity
Profitability
Research Rates
Investment Rates
Performance Indicators:
(Using Pharmaceutical Sales as an example)
Companies by Pharmaceutical Sales 2005-2009 (US$m)
Companies by Yearly Change (Local Currency)
Companies by Five-Year Change (Local Currency)
Five-Year Movement of Pharmaceutical Sales
(2000 constant US$ Exchange Rates)
Five-Year Change in Pharmaceutical Sales
(Index Numbers)

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/121440_pharmaceutical_companie...

About Espicom Business Intelligence

Espicom Business Intelligence is a highly-regarded and established provider of business intelligence services. Founded in 1982 as MDIS Publications Ltd, the company changed its name to Espicom in 1992. Initially a publisher in a wide range of industries such as power generation and telecommunications, they now focus on the global pharmaceutical and medical device sectors.  View more research from Espicom Business Intelligence at http://www.fastmr.com/catalog/publishers.aspx?pubid=1025

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.